Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Baxter
McKesson
Merck

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR CATHFLO ACTIVASE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for CATHFLO ACTIVASE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00265005 ↗ Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants Terminated Genentech, Inc. Phase 1 2005-06-01 The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
NCT00265005 ↗ Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants Terminated University of Louisville Phase 1 2005-06-01 The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.
NCT00307580 ↗ Cathflo Activase Pediatric Study Completed Genentech, Inc. Phase 4 2002-04-01 This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at ~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase.
NCT00784134 ↗ Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III Completed Emissary International LLC Phase 3 2009-07-01 The overall objective of this Phase III clinical trial is to obtain information from a population of 500 ICH subjects with intraventricular hemorrhage (IVH), representative of current clinical practice and national demographics of ICH regarding the benefit (or lack thereof) of IVH clot removal on subject function as measured by modified Rankin Scale (mRS). This application requests funding for five years to initiate a Phase III randomized clinical trial (RCT) testing the benefit of clot removal for intraventricular hemorrhage. The investigators propose to compare extraventricular drainage (EVD) use plus recombinant tissue plasminogen activator (rt-PA; Alteplase; Genentech, Inc., San Francisco, CA) with EVD+ placebo in the management and treatment of subjects with small intracerebral hemorrhage (ICH) and large intraventricular hemorrhage (IVH defined as ICH < 30 cc and obstruction of the 3rd or 4th ventricles by intraventricular blood clot).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CATHFLO ACTIVASE

Condition Name

Condition Name for CATHFLO ACTIVASE
Intervention Trials
Dysfunctional Central Venous Access Devices (CVADS) 1
Intraventricular Hemorrhage 1
Pleural Effusion 1
Thrombosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CATHFLO ACTIVASE
Intervention Trials
Hemorrhage 1
Cerebral Hemorrhage 1
Thrombosis 1
Pleural Effusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CATHFLO ACTIVASE

Trials by Country

Trials by Country for CATHFLO ACTIVASE
Location Trials
United States 26
Brazil 2
United Kingdom 2
Hungary 2
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CATHFLO ACTIVASE
Location Trials
Florida 2
Kentucky 1
North Carolina 1
Ohio 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CATHFLO ACTIVASE

Clinical Trial Phase

Clinical Trial Phase for CATHFLO ACTIVASE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CATHFLO ACTIVASE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CATHFLO ACTIVASE

Sponsor Name

Sponsor Name for CATHFLO ACTIVASE
Sponsor Trials
Genentech, Inc. 4
University of Louisville 1
Emissary International LLC 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CATHFLO ACTIVASE
Sponsor Trials
Industry 5
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.